BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35139733)

  • 1. Bilateral adrenal primary tumor in Stage 4S neuroblastoma: The Italian experience and review of the literature.
    Montalto S; Sertorio F; Podda M; Sorrentino S; Di Cataldo A; Provenzi M; Nonnis A; D'Ippolito C; Corrias MV; De Bernardi B
    Pediatr Hematol Oncol; 2022 Aug; 39(5):441-452. PubMed ID: 35139733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of stage 4S composite neuroblastoma with a MYCN-amplified nodule.
    Bishop MW; Yin H; Shimada H; Towbin AJ; Miethke A; Weiss B
    J Pediatr Hematol Oncol; 2014 Jan; 36(1):e31-5. PubMed ID: 23528904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.
    Vo KT; Matthay KK; Neuhaus J; London WB; Hero B; Ambros PF; Nakagawara A; Miniati D; Wheeler K; Pearson AD; Cohn SL; DuBois SG
    J Clin Oncol; 2014 Oct; 32(28):3169-76. PubMed ID: 25154816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.
    Alvarado CS; London WB; Look AT; Brodeur GM; Altmiller DH; Thorner PS; Joshi VV; Rowe ST; Nash MB; Smith EI; Castleberry RP; Cohn SL
    J Pediatr Hematol Oncol; 2000; 22(3):197-205. PubMed ID: 10864050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilateral adrenal neuroblastoma.
    Pagès PM; Dufour C; Fasola S; Michon J; Boutard P; Gentet JC; Hartmann O
    Pediatr Blood Cancer; 2009 Feb; 52(2):196-202. PubMed ID: 18951434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study.
    Nickerson HJ; Matthay KK; Seeger RC; Brodeur GM; Shimada H; Perez C; Atkinson JB; Selch M; Gerbing RB; Stram DO; Lukens J
    J Clin Oncol; 2000 Feb; 18(3):477-86. PubMed ID: 10653863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [4S neuroblastoma with bilateral adrenal tumors].
    Kerdudo C; Corradini N; Michon J; Leverger G
    Arch Pediatr; 2004 Dec; 11(12):1450-6. PubMed ID: 15596333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.
    Twist CJ; Naranjo A; Schmidt ML; Tenney SC; Cohn SL; Meany HJ; Mattei P; Adkins ES; Shimada H; London WB; Park JR; Matthay KK; Maris JM
    J Clin Oncol; 2019 Jan; 37(2):115-124. PubMed ID: 30444686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
    Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
    J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age.
    Taggart DR; London WB; Schmidt ML; DuBois SG; Monclair TF; Nakagawara A; De Bernardi B; Ambros PF; Pearson AD; Cohn SL; Matthay KK
    J Clin Oncol; 2011 Nov; 29(33):4358-64. PubMed ID: 21969516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable histology, MYCN-amplified 4S neonatal neuroblastoma.
    Chan EL; Harris RE; Emery KH; Gelfand MJ; Collins MH; Gruppo RA
    Pediatr Blood Cancer; 2007 Apr; 48(4):479-82. PubMed ID: 16333837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S.
    Bénard J; Raguénez G; Kauffmann A; Valent A; Ripoche H; Joulin V; Job B; Danglot G; Cantais S; Robert T; Terrier-Lacombe MJ; Chassevent A; Koscielny S; Fischer M; Berthold F; Lipinski M; Tursz T; Dessen P; Lazar V; Valteau-Couanet D
    Mol Oncol; 2008 Oct; 2(3):261-71. PubMed ID: 19383347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
    J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYCN gain and MYCN amplification in a stage 4S neuroblastoma.
    Noguera R; Cañete A; Pellín A; Ruiz A; Tasso M; Navarro S; Castel V; Llombart-Bosch A
    Cancer Genet Cytogenet; 2003 Jan; 140(2):157-61. PubMed ID: 12645655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group.
    Kawano A; Hazard FK; Chiu B; Naranjo A; LaBarre B; London WB; Hogarty MD; Cohn SL; Maris JM; Park JR; Gastier-Foster JM; Ikegaki N; Shimada H
    Am J Surg Pathol; 2021 Aug; 45(8):1075-1081. PubMed ID: 33739795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of surgical radicality on outcome in childhood neuroblastoma.
    von Schweinitz D; Hero B; Berthold F
    Eur J Pediatr Surg; 2002 Dec; 12(6):402-9. PubMed ID: 12548494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Features and outcome of neuroblastoma detected before birth.
    Granata C; Fagnani AM; Gambini C; Boglino C; Bagnulo S; Cecchetto G; Federici S; Inserra A; Michelazzi A; Riccipetitoni G; Rizzo A; Tamaro P; Jasonni V; De Bernardi B
    J Pediatr Surg; 2000 Jan; 35(1):88-91. PubMed ID: 10646781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study.
    Nuchtern JG; London WB; Barnewolt CE; Naranjo A; McGrady PW; Geiger JD; Diller L; Schmidt ML; Maris JM; Cohn SL; Shamberger RC
    Ann Surg; 2012 Oct; 256(4):573-80. PubMed ID: 22964741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.